(March 10, 2017, 7:23 AM EST) -- SAN FRANCISCO — A lead plaintiff in a securities class action lawsuit against a biotechnology company and certain of its current and former executive officers has failed to plead specificity or falsity in making claims that the defendants issued misrepresentations concealing issues with its suite of products, certain collaborations and revenue disclosures in violation of federal securities law, a federal judge in California ruled Feb. 24 in granting the defendants’ motion to dismiss (In re Intrexon Corp. Securities Litigation, No. 16-2398, N.D. Calif., 2017 U.S. Dist. LEXIS 26401)....